Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00475969 · ClinicalTrials.gov registry record · Phase 3
Duloxetine vs Placebo in the Treatment of General Anxiety
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 327
- Enrollment target
NCT00475969 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 327 participants.
The verdict
NCT00475969, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 327 participants
- Enrollment target
Study Summary
To see if duloxetine 60 to 120 mg once daily (QD) is better than placebo in the treatment of generalized anxiety disorder (GAD).
Interventions
- DRUG placebo
- DRUG duloxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 327 participants |
| Start Date | 2004-08 |
| Est. Completion | 2005-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00475969
The ClinicalTrials.gov registry entry for NCT00475969 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 327 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00475969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00475969 about?
NCT00475969 is a clinical study titled "Duloxetine vs Placebo in the Treatment of General Anxiety". To see if duloxetine 60 to 120 mg once daily (QD) is better than placebo in the treatment of generalized anxiety disorder (GAD).
What is the current status of trial NCT00475969?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 327 participants. The study started on 2004-08. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00475969?
The interventions under investigation include: placebo (DRUG), duloxetine (DRUG).
Who is sponsoring clinical trial NCT00475969?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.